It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Deerfield-based Baxter International Inc. says it is looking into building a cell-based vaccine manufacturing plant in the U.S. to produce seasonal and pandemic flu vaccines
The company won't say when a plant could be built because the timing would depend on the outcome of a government-funded clinical trial of its seasonal product, which is in its final stages. A timetable will be clearer when the company can determine the success of its seasonal and pandemic flu vaccine development program
Baxter is the latest drugmaker to express interest in the potentially lucrative business of producing vaccines in the U.S. Although companies historically have complained of little profit from flu vaccines, increased government subsidies are making the business more attractive
Swiss drug giant Novartis AG earlier this week began design and construction on a $1 billion cell-based manufacturing plant in North Carolina, which is backed by more than $400 million in federal funds
the commission is pushing the U.S. to spend $3 billion a year -- 10 times the annual spending currently budgeted -- to enhance "U.S. vaccine preparedness." The commission also is trying to mobilize the public behind its effort through its Web site, FasterVaccines.org.
For its part, the FDA said it can't comment on Baxter's trial or any expected application for approval
Plus, as anyone who knows anything about negotiating knows, you start way above what you need in price. Baxter was smart in doing this, too, because the nation is afraid of H1N1, and so they went public with their plans and cost. Now it's on the politicians to convince the public they don't need $10B invested in the health of America. With a multi-trillion dollar health bill before congress, that's not going to be easy
Originally posted by grantbeed